SpringWorks Therapeutics Inc
NASDAQ:SWTX

Watchlist Manager
SpringWorks Therapeutics Inc Logo
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Watchlist
Price: 36.825 USD 3.47% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
SpringWorks Therapeutics Inc?
Write Note

SpringWorks Therapeutics Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SpringWorks Therapeutics Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Net Issuance of Common Stock
$296.6m
CAGR 3-Years
3%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Issuance of Common Stock
-$1.1B
CAGR 3-Years
-10%
CAGR 5-Years
16%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Common Stock
-$782m
CAGR 3-Years
11%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Common Stock
-$243.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

SpringWorks Therapeutics Inc
Glance View

Market Cap
2.7B USD
Industry
Biotechnology

SpringWorks Therapeutics Inc., a cutting-edge biopharmaceutical company, emerged from its inception as a strategic spin-out venture from the global pharmaceutical giant Pfizer. Born in 2017, the company cleverly positions itself at the forefront of the drug development process, with a keen focus on targeting rare diseases and cancer. SpringWorks leverages its robust pipeline of therapies, specifically designed to address significant unmet medical needs. Their approach revolves around the repurposing and reinvigoration of underappreciated and overlooked clinical molecules, which previously lacked the necessary backing to reach the market. This innovative approach allows SpringWorks to harness upstream R&D efforts while minimizing the typical time and resources required for de novo drug development. Earning its stripes in the field, SpringWorks generates revenue primarily through milestone and royalty agreements tied to its partnerships and co-development collaborations. Rather than relying solely on traditional sales of approved drugs, the company emphasizes strategic alliances with research institutions and pharmaceutical partners to advance its drug candidates. This co-development model extends its reach and augments the company's research capabilities, enabling SpringWorks to share risks and tap into broader resources. By nurturing innovations through collaboration, SpringWorks not only enriches its pipeline but also stands as a vanguard in transforming potential therapies into commercial realities, ultimately positioning itself as a linchpin in the orphan disease market.

SWTX Intrinsic Value
31.581 USD
Overvaluation 14%
Intrinsic Value
Price

See Also

What is SpringWorks Therapeutics Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
296.6m USD

Based on the financial report for Dec 31, 2023, SpringWorks Therapeutics Inc's Net Issuance of Common Stock amounts to 296.6m USD.

What is SpringWorks Therapeutics Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
43%

Over the last year, the Net Issuance of Common Stock growth was -13%. The average annual Net Issuance of Common Stock growth rates for SpringWorks Therapeutics Inc have been 3% over the past three years , 43% over the past five years .

Back to Top